The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.
Immediate antiretroviral treatment (ART) for people with low CD4 counts in China reduces overall mortality by 63% – confirming trials in other countries that have shown the benefit of early treatment for improved health outcomes.
The country with the third largest HIV epidemic moves to a test-and-treat strategy that aims to get everyone on antiretroviral therapy.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.
HIV drugs should now be more accessible in India, after the country’s National List of Essential Medicines (NLEM) was expanded to include antiretrovirals (ARVs) and many other medicines.
New HIV infections among children in Asia have fallen by over 25% in fifteen years thanks to improved HIV testing and treatment for pregnant women.
A delayed tendering process for antiretroviral drugs by the Indian National AIDS Control Organisation (NACO) meant that 150,000 people living with HIV (PLHIV) in India were at risk of being without antiretroviral treatment (ART) for October. This is a continuation of the drugs crisis AVERT reported on last month, which saw NACO having issues procuring drugs. Recently, a coalition of Indian pharmaceutical companies, the World Health Organisation (WHO), Medicine San Frontier (MSF) and others have come together to fill the gap of missing drugs.
HIV drug shortages in India over the past few months have meant that many people living with HIV (PLHIV) are unable to access antiretroviral treatment (ART) through government run distribution centres. Thousands of PLHIV rely on the free ART provided by India’s National AIDS Control Organization (NACO), however they are facing drug shortfalls that are largely blamed on supply bottlenecks, late payments to pharmaceutical companies and Indian manufacturers boycotting the process.